Sat, Aug 2, 2025
1- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Gorgan, Iran , baniaghil1344@yahoo.com
2- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
3- , Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Gorgan, Iran
2- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
3- , Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Gorgan, Iran
Abstract: (122 Views)
Background: One of the major complications in thalassemia patients is alloimmunization, which is antibody production by the patient against transfused RBCs (red blood cells). In the present study, the frequency of alloantibodies in thalassemia patients was investigated.
Materials and Methods: In this cross-sectional retrospective study, the study was performed on ninety nine multi-transfused thalassemia patients, antibody screening test was carried out using three cell-panel. Positive patients were followed up for antibody identification using 11-cell panel. The information was finally analyzed using SPSS software version 16.0.
Results: Out of ninety-nine cases, 53 were female (53.53 %) and 46 male (46.46 %). The patient’s age mean was 29.22±10.46 years with 2 to 61 years age range. Only 5.05% (N=5) had developed alloantibodies. The most common alloantibodies were Anti-D, Anti-E, Anti-c and Anti-K. No significant correlation was seen between the presence of alloantibody and age, sex, blood type and spleen condition.
Conclusion: Antibody production against RBC antigens is a common problem in multi-transfused thalassemia patients. Compatibility between antigens of Kell and Rh blood group systems in donors and recipients can be one of the useful ways to prevent alloimmunization of blood recipients and the production of unexpected antibodies against donor’s red blood cells.
Materials and Methods: In this cross-sectional retrospective study, the study was performed on ninety nine multi-transfused thalassemia patients, antibody screening test was carried out using three cell-panel. Positive patients were followed up for antibody identification using 11-cell panel. The information was finally analyzed using SPSS software version 16.0.
Results: Out of ninety-nine cases, 53 were female (53.53 %) and 46 male (46.46 %). The patient’s age mean was 29.22±10.46 years with 2 to 61 years age range. Only 5.05% (N=5) had developed alloantibodies. The most common alloantibodies were Anti-D, Anti-E, Anti-c and Anti-K. No significant correlation was seen between the presence of alloantibody and age, sex, blood type and spleen condition.
Conclusion: Antibody production against RBC antigens is a common problem in multi-transfused thalassemia patients. Compatibility between antigens of Kell and Rh blood group systems in donors and recipients can be one of the useful ways to prevent alloimmunization of blood recipients and the production of unexpected antibodies against donor’s red blood cells.
Research Article: Research Article |
Subject:
Laboratory Sciences
Received: 2023/09/27 | Accepted: 2024/01/2
Received: 2023/09/27 | Accepted: 2024/01/2
References
1. Sahu A, Parida P, Mahapatra S, Sahoo BB. Detection of red cell alloantibodies in thalassaemia patients. Int J Contemp Pediatr. 2020;7(2):419-23. [View at Publisher] [DOI] [Google Scholar]
2. Fergus N. An overview of thalassemia for parent adapting international health and medicine. Available at: www.comeunity.com/adoption/health /thalassemia. Html. 2002. [View at Publisher]
3. Sarookhani MR, Ahmadi MH. Rare and unexpected beta thalassemic mutations in Qazvin province of Iran. Afr J Biotechnol. 2010;9(1):95-101. [View at Publisher] [Google Scholar]
4. Najmabadi H, Teimorian S, Khatibi T, Neishabory M, Pourfarzad F, Jalil S,et al. Amplification refractory mutation system (ARMS) AND reverse hybridizationin the detection of beta thalassemia mutation. Haematologica. 2002;87:1114-16.
5. Derakhshandeh-Peykar P, Akhavan-Niaki H, Tamaddoni A, Ghawidel-Parsa S, Holakouie Naieni K, Rahmani M, et al. Distribution of beta-thalassemia mutations in the northern provinces of Iran. Hemoglobin. 2007;31(3):351-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Van Buren NL, Gorlin JB, Corby SM, Cassidy S, FritchLilla S, Nelson SC, et al. How do I incorporate red cell genotyping to improve chronic transfusion therapy? Transfusion. 2020;60(1):16-25. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006; 37(1):12-20. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Vaziri M, JavadzadehShahshahani H, Moghaddam M, Taghvaee N. Prevalence and specificities of red cell alloantibodies in transfusion-dependent beta thalassemia patients in Yazd. Iran J Ped Hematol Oncol. 2015;5(2):93-9. [View at Publisher] [PMID] [Google Scholar]
9. Prati D. Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major. Vox Sang. 2000;79(3):129-37. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Ye Z, Zhang D, Boral L, Liz C, May J. Comparison of blood group molecular genotyping to traditional serological phenotyping in patients with chronic or recent blood transfusion. JBM. 2016;4(03):1-8. [View at Publisher] [DOI] [Google Scholar]
11. Dunbar NM, Szczepiorkowski ZM. How do we utilize a transfusion safety officer? Transfusion. 2015;55(9):2064-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusiondependent thalassemia patients of predominantly Asian descent. Blood. 2000;96(10):3369-73. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Keikhaei B, Hirad Far A, Abolghasemi H, et al. Red Blood Cell Alloimmunization in Patients with Thalassemia Major and Intermediate in Southwest Iran. Iranian Journal of Blood and Cancer. 2013;6(1):41-6. [View at Publisher] [Google Scholar]
14. Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood. 2000;96(10):3369-73. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Das SS, Biswas RN, Safi M, Zaman RU. Alloimmunization to erythrocyte antigens in patients receiving multiple blood transfusions: Clinico-immunohematological and demographic risk factors and impact of extended red cell phenotyping. Glob J Transfus Med. 2021;6(2):171-7. [View at Publisher] [DOI] [Google Scholar]
16. Shamsian BS, Arzanian MT, Shamshiri AR, Alavi S, Khojasteh O. Frequency of red cell alloimmunization in patients with-major thalassemia in an Iranian Referral Hospital. Iran J Pediatr. 2008;18(2):149-53. [View at Publisher] [Google Scholar]
17. Karimi M, Nikrooz P, Kashef S, Jamalian N, Davatolhagh Z. RBC alloimmunization in blood transfusion-dependent betathalassemia patients in southern Iran. Int J Lab Hematol. 2007;29(5):321-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Keikhaei B, Hirad Far A, Abolghasemi H, Mousakhani H, Ghanavat M, Moghadam M, et al. Red blood cell alloimmunization in patients with thalassemia major and intermediate in southwest Iran. IJBC. 2013;6(1):41-6 [View at Publisher] [Google Scholar]
19. Sadeghian MH, Keramati MR, Badiei Z, Ravarian M, Ayatollahi H, Rafatpanah H, et al. Alloimmunization among transfusion-dependent thalassemia patients. Asian J Transfus Sci. 2009;3(2):95-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Mirzaeian A, Tamaddon G, Naderi M, Hosseinpour M, Sargolzaie N, Dorgalaleh A, et al. Prevalence of alloimmunization against RBC antigens in thalassemia major patients in south east of Iran. J Blood Disorders Transf. 2013;4(4):1-4 [View at Publisher] [DOI] [Google Scholar]
21. Ghorbani AA E, Tavassoli AR, Gharehbaghian A, Kasraian L, Khademi R, Taleie A. Evaluation of frequency and specificity of RBC alloantibodies in Namazi Hospital patients in Shiraz, 2010. Sci J Iranian Blood Trans Organ. 2013;10(3):239-45. [View at Publisher] [Google Scholar]
22. Kiani A, Abdi J, Shirkhani Y, Kashi M. Prevalence of alloimmunization against RBC antigens in thalassemia major patients of Lorestan province in 2004. Sci J Iran Blood Transfus Organ. 2006;3(3):265-71. [View at Publisher] [Google Scholar]
23. Kosaryan M, Mahdavi MR, Roshan P, Hojjati MT. Prevalence of alloimmunisation in patients with beta thalassemia major. Blood Transfus. 2012;10(3):396-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
24. Azarkeivan A, Ansari S, Ahmadi MH, Hajibeigy B, Maghsudlu M, Nasizadeh S, et al. Blood transfusion and alloimmunization in patients with thalassemia: Multicenter study. Pediatr Hematol Oncol. 2011;28(6):479-85. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Darvishi P, Azami M, Sayehmiri K, Sayehmiri F, Goodarzi A, Azarkeivan A, et al. Red blood cell alloimmunization in Iranian beta thalassemia patients: a systematic review and meta-analysis. ISBT Science Series. 2016;11(3):163-73. [View at Publisher] [DOI] [Google Scholar]
26. Rostamian H, Javandoost E, Mohammadian M, Alipour A. Prevalence and specificity of red blood cell alloantibodies and autoantibodies in transfused Iranian β thalassemia patients: A systematic review and meta analysis. Asian J Transfus Sci. 2022;16(1):111-20. [View at Publisher] [DOI] [PMID] [Google Scholar]
27. Shaiegan M, Moghaddam M, Maghsudlu M, Azarkeivan A, Zolfaghari S, Pourfatollah AA, et al. Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients. Int J Hematol Oncol Stem Cell Res. 2022;16(1):9-14. [View at Publisher] [DOI] [PMID] [Google Scholar]
28. Dean L. Blood groups and red cell antigens. Bethesda (MD): National Center for Biotechnology Information (US); 2005. [View at Publisher] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.